Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone versus placebo for prevention of atherosclerosis progression in high-risk men with metabolic syndrome
NL-OMON24183Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in cardiometabolic risk (CMR) and atherosclerosis comparing Rosiglitazone plus lifestyle intervention with Placebo plus lifestyle intervention (2 arms). Primary endpoints: Magnetic resonance assessment of carotid artery wall and Magnetic resonance measurement of fat stores. Started Sep 2005; status: active, not recruiting.
02
Drugs
rosiglitazone
03
Conditions
cardiometabolic risk (CMR)atherosclerosis
Beyond the preview
Go deeper on NL-OMON24183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24183.